In colon cancer cell lines with mutated KRAS, compound 2d (one basic side chain) has 5–10 fold higher activity (IC50 values of 0.14–0.50 μM) compared to the established anticancer drug 5-FU (2.38–5.39 μM), whereas 3d and 3e (two basic side chains) were less effective than 2d, but equally (3d) or more (3e) effective than 5-FU and significantly more than TMPyP4. This evidence concerns the gene KRAS and malignant colon neoplasm.